
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp demonstrates a strong potential for continued growth, supported by vaccine response rates for its 100ug candidate that are comparable to those of Shingrix, while also exhibiting significantly better tolerability. The company’s shingles vaccine candidate has achieved results that align well with management's immunogenicity and tolerability goals, reinforcing the efficacy of its innovative platform. Furthermore, positive results related to CD4+ T-cell responses for its Z-1018 candidate further bolster Dynavax's outlook, making it a compelling player in the biopharmaceutical landscape.
Bears say
Dynavax Technologies Corp faces significant risks in developing its product candidates, as any future candidates may fail to meet efficacy endpoints or exhibit safety issues that could impede their approval and commercialization. The company also faces challenges related to market conditions and competition that could hinder the effective commercialization of its proprietary candidates, further compromising its revenue potential. Additionally, there is a risk associated with the ability to secure acceptable partnership terms for its candidates, which could jeopardize successful market launches and adversely impact the company's financial outlook.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares